Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Esomeprazole (Nexium® IV) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0712. 2012 Authors' conclusions Esomeprazole (Nexium® IV) is recommended as an option for use within NHS Wales for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1–18 years of age.
AWMSG is of the opinion that esomeprazole (Nexium® IV) is suitable for specialist only prescribing within NHS Wales for the above indication. Indexing Status Subject indexing assigned by CRD Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000340 Date abstract record published 08/08/2012 |